Drug Catalog - Product Detail
IPRATROPIUM BROMIDE INHAL SOL (SINGLE-PAK) SOL 0.0002 30X3ML
| NDC | Mfr | Size | Str | Form |
|---|---|---|---|---|
| 00378-6989-93 | MYLAN | 2ML | 0.02% | NA |
Generic Name
Substance Name
Product Type
Route
Application Number
Description
DESCRIPTION The active ingredient in Ipratropium Bromide Inhalation Solution is ipratropium bromide monohydrate, USP. It is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo[3.2.1]-octane,3-(3-hydroxy-1-oxo-2-phenylpropoxy)- 8-methyl-8-(1-methylethyl)-, bromide, monohydrate (endo, syn)-,(±)-; a synthetic quaternary ammonium compound, chemically related to atropine. Ipratropium bromide is a white crystalline substance, freely soluble in water and lower alcohols. It is a quaternary ammonium compound and thus exists in an ionized state in aqueous solutions. It is relatively insoluble in non-polar media. Ipratropium Bromide Inhalation Solution is administered by oral inhalation with the aid of a nebulizer. Each mL contains ipratropium bromide, USP 0.02%(anhydrous basis) in a sterile, preservative-free, isotonic saline solution, pH adjusted to 3.4 (3 to 4) with hydrochloric acid. Ipratropium Bromide Structural Formula
How Supplied
HOW SUPPLIED Ipratropium Bromide Inhalation Solution is a clear, colorless solution supplied in a unit-dose vial containing 2.5 mL. Supplied in cartons as listed below: NDC 0378-6989-93 30 vials per carton/1 vial per foil pouch Each vial is made from a low density polyethylene (LDPE) resin. Store between 15° and 30°C (59° and 86°F). Protect from light. Store in pouch until time of use. ATTENTION PHARMACIST: Detach “Patient’s Instructions for Use” from Package Insert and dispense with solution. Rx only. Manufactured by: Mylan Specialty L.P. Napa, CA 94558 Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 MS:IPBRIS:R1 JUL 12 03-934-02
Indications & Usage
INDICATIONS AND USAGE Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Dosage and Administration
DOSAGE AND ADMINISTRATION The usual dosage of Ipratropium Bromide Inhalation Solution is 500 mcg (1 Unit-Dose Vial) administered three to four times a day by oral nebulization, with doses 6 to 8 hours apart. Ipratropium Bromide Inhalation Solution Unit-Dose Vials contain 500 mcg ipratropium bromide, USP anhydrous in 2.5 mL normal saline. Ipratropium Bromide Inhalation Solution can be mixed in the nebulizer with albuterol or metaproterenol if used within one hour. Drug stability and safety of Ipratropium Bromide Inhalation Solution when mixed with other drugs in a nebulizer have not been established.